Medtronic(NYSE) MDT

Medtronic plc makes tools that help doctors treat heart and brain problems. These devices help people manage illnesses like diabetes and chronic pain. The company sells these products to hospitals around the world.

Inside the Product Portfolio

• Cardiovascular Portfolio: Heart valves and pacing tools for heart rhythm diseases; generated $3.9 billion in net sales for the three months ended July 31, 2026.
• Neuroscience Portfolio: Spinal implants, robotic guidance systems, and therapies for brain disorders; generated $2.7 billion in net sales for the three months ended July 31, 2026.
• Medical Surgical Portfolio: Surgical stapling devices, vessel sealing instruments, and robotic-assisted surgery systems; generated $2.3 billion in net sales for the three months ended July 31, 2026.
• Diabetes Operating Unit: Insulin pumps, continuous glucose monitoring systems, and smart insulin pen technologies; generated $843 million in net sales for the three months ended July 31, 2026.

Fresh Deals and Big Changes

• Acquired CathWorks Ltd in April 2026 to expand tools used for diagnosing and treating coronary artery disease.
• Closed the acquisition of Scientia Vascular on June 12, 2026, to add access products used for complex neurovascular conditions.
• Purchased SPR Therapeutics on July 16, 2026, to integrate peripheral nerve stimulation technology for patients with chronic pain.
• Separated the Diabetes Business into an independent, publicly traded company named MiniMed Group, which completed its initial public offering on March 9, 2026.

Built for Modern Surgery

The company operates a global network serving healthcare systems and physicians across multiple medical specialties. Medtronic integrates artificial intelligence and robotic-assisted platforms into its surgical and spinal procedural tools.

Recent Performance at a Glance

• Total net sales reached $9.8 billion for the three months ended July 31, 2026, up 14% year over year.
• Net income attributable to the company was $1.5 billion for the three months ended July 31, 2026, compared to $1.0 billion in the prior year.
• Free cash flow, which is a non-GAAP measure of cash from operations minus equipment costs, rose to $1.3 billion for the three months ended July 31, 2026.
• The company repurchased 3 million ordinary shares at an average price of $81.56 during the first quarter of fiscal year 2027.
• Total debt stood at $28.2 billion as of July 31, 2026, slightly higher than the $28.0 billion reported on April 24, 2026.

Bottom Line

Medtronic has transitioned from a traditional medical device manufacturer into a diversified healthcare technology company using digital and robotic solutions. Its expansion into advanced diagnostics and specialized therapies supports its long-term relevance in global surgical markets.